References
- Lieschke JG, Burgess WA. Granulocyte-colony stimulat-ing factor and granulocyte macrophage-colony stimulating factor. N Engl J Med 1992; 322: 28–35.
- Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factors: biology and clinical Applications. N Engl J Med. 1989; 321: 1449–1459.
- Cebon JS, Lieschke GJ. Granulocyte-macrophage colony-stimulating factor for cancer treatment. Oncology. 1994; 51: 177–188.
- Wills JA. Myeloprotective effect of high-dose medrox-yprogesterone acetate. Chemioterapia 1988; 7 (1): 60–62.
- Quesada AR, Jimone JM, Marquez G, Aracil M. Cell cycle arrest of human hematopoietic progenitors induced by medroxyprogesterone acetate. Exp Hematol 1993; 21: 1413–1418.
- Spriggs DR. Tumor necrosis factor: basic principles and preclinical studies. In: Biological therapy of cancer. De Vita VT, Hellman S and Rosenberg SA ( eds). Philadelphia: JB Lippincott Company, 1991: 345-377.
- Bukowski RM, McLain D, Finke J. Clinical pharmacoki-netics of interleukin 1, interleukin 2, interleukin 4, tumor necrosis factor and macrophage colony-stimulating factor. In: Cancer chemotherapy and biotherapy. Chabner BA, Longo DL ( eds). Philadelphia: Lippincott-Raven, 1995: 609-638.
- Harmenberg J, Hoglund M, Hellstrom-Linberg E. G-and GM-CSF in oncology and oncological haematology. Eur J Haematol 1994; 52: 1–28.
- Focan C, Baudoux A, Beauduin M et al. Improvement of hematological and general tolerance to CMF by high-dose medroxyprogesterone acetate adjuvant treatment for primary node positive breast cancer (Analysis of 100 patients). Anticancer Res 1986; 6: 1095–1100.
- Tominaga T, Abe 0, Ohshima A et al. Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced recurrent breast cancer. Eur J Cancer 1994; 30A: 959–964.
- Amadori D, Frassineti GL, Flamini et al. Clinical and laboratory evaluation of the myeloprotective effect of medroxyprogesterone acetate in head and neck cancer. Eur J Cancer 1992; 28A: 1331–1334.
- Pedrazzoli P, Bacciocchi G, Antonio De Proda G et al. Evaluation of the effect of medroxyprogesterone acetate on bone marrow progenitor cells. Tumori 1991; 77: 399–402.
- Umbach GE, Spitzer G, Drewinko B, Gercovich G, Hortobagy G. Medroxyprogesterone acetate does not protect human bone marrow progenitor cells exposed to Adriamycin in vitro. Breast Cancer Res Treat 1985; 5: 87–89.
- Abrahamsson J, Carlsson B, Mellander L. Tumor necrosis factor-a in malignant disease. Am J Pediatr Hematol Oncol 1993; 15 (4): 364–369.
- Murase T, Hotta T, Saito H, Ohno R. Effect of recom-binant human tumor necrosis factor on the growth of human leukemia progenitor cell and normal hematopoietic progeni-tor cells. Blood, 1987; 69 (2): 467–472.
- Gough DB, Winstanley FP, Fearon KCH, Carter DC. Regulation of tumor necrosis factor production in healthy humans and in patients with cancer. Arch Surg 1992; 127: 713–717.
- Herrmann JL, Blanchard H, Brunengo P, Lagrange PH. TNF-a, IL-1(3 and IL-6 plasma levels in neutropenic patients after onset of fever and correlation with the C-reac-tive protein (CRP) kinetic values. Infection 1994; 22 (5); 309-315.
- Shitara T, Yugami SI, Ijima, Sotomatu M, Kuroume T. Cytokine profile during high-dose rh G-CSF therapy in severe congenital neutropenia. Am J Hematol 1994; 45: 58–62.
- Engervall P, Andersson B, Björkholm M. Clinical sig-nificance of serum cytokine patterns during start of fever in patients with neutropenia. Br J Haematol 1995; 91: 838–845.
- Tuncer AM, Higsönmez G, Gflmrflk F et al. Serum TNF-alpha, gamma-INF, G-CSF and GM-CSF levels in neu-tropenic children with acute leukemia treated with short-course, high-dose methylprednisolone. Leuk Res 1996; 20 (3): 265–269.
- Broxmeyer HE, Williams DE, Lu L et al. The suppres-sive influences of human tumor necrosis factors on bone mar-row hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon. J Immunol 1986; 136 (12): 4487–4495.
- Kleeber UR, Schneider P, Kern P. Myeloprotective effect of medroxyprogesterone acetate on committed granu-lopoietic stem cells under cytotoxic chemotherapy. Anticancer Res 1986; 6: 393 (abstr).